Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Work In Process (2016 - 2017)

Vanda Pharmaceuticals (VNDA) has disclosed Work In Process for 4 consecutive years, with $80000.0 as the latest value for Q4 2017.

  • Quarterly Work In Process rose 370.59% to $80000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $80000.0 through Dec 2017, up 370.59% year-over-year, with the annual reading at $80000.0 for FY2017, 370.59% up from the prior year.
  • Work In Process hit $80000.0 in Q4 2017 for Vanda Pharmaceuticals, up from $63000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.8 million in Q2 2015 to a low of $7000.0 in Q2 2014.
  • Historically, Work In Process has averaged $564833.3 across 4 years, with a median of $71500.0 in 2017.
  • Biggest five-year swings in Work In Process: surged 25300.0% in 2015 and later soared 370.59% in 2017.
  • Year by year, Work In Process stood at $1.3 million in 2014, then rose by 19.0% to $1.6 million in 2015, then tumbled by 98.92% to $17000.0 in 2016, then skyrocketed by 370.59% to $80000.0 in 2017.
  • Business Quant data shows Work In Process for VNDA at $80000.0 in Q4 2017, $63000.0 in Q3 2017, and $131000.0 in Q2 2017.